



Suggested Formula	Cyclosporine 100 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 615
-------------------	--	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Cyclosporin A (Cyclosporine), USP	3.000	g				
Dehydrated Alcohol, USP	3.8	mL				
Oleoyl Polyoxylglycerides, NF	7.3	mL				
Olive Oil, NF	q.s. to 30.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light sensitive (protect from light whenever possible):

Cyclosporin A (Cyclosporine)

Narrow Therapeutic Index

Cyclosporin A (Cyclosporine)

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error /
Testing Considerations:

To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction:

Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

Cyclosporin A (Cyclosporine) has a Narrow Therapeutic Index.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Cyclosporine 100 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 615
-------------------	--	-----	-----------

SUGGESTED PREPARATION (for 30 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : ____	Processing Error	Qty. to measure
Cyclosporin A (Cyclosporine), USP §	3.000	g			
Dehydrated Alcohol, USP	3.8	mL			
Oleoyl Polyoxylglycerides, NF	7.3	mL			
Olive Oil, NF	q.s. to 30.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

1.	<u>Powder-Liquid Preparation:</u> A. Combine and mix the following ingredients together to form a homogeneous liquid-like solution: -Dehydrated Alcohol -Oleoyl Polyoxylglycerides B. Incrementally add the Cyclosporin A (Cyclosporine) to the homogeneous liquid-like solution (Step 1A). <u>Specifications:</u> Continuously mix until all solid particles have completely dissolved. <u>End result:</u> Homogeneous liquid-like solution.
4.	<u>Filling to volume:</u> A. Add Olive Oil to the mixture (Step 1B) to fill to the required batch size (30.0 mL <i>plus</i> processing error adjustments). <u>Specifications:</u> Continuously mix. <u>End result:</u> Homogeneous liquid-like solution.
5.	<u>Product transfer:</u> Transfer the final product into the specified dispensing container (see “Packaging requirements”).



Suggested Formula	Cyclosporine 100 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 615
-------------------	--	-----	-----------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	30 days as per USP.	Packaging Requirements	Tight, light-resistant dispensing bottle with a metered dosing device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	5	Protect from light.
	2	Keep out of reach of children.	6	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	3	Cap tightly after use.	7	Keep in a dry place.
	4	Keep cool but do not refrigerate.	8	
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. IMPORTANT: To be dispensed and administered only under the close supervision of the prescribing physician.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Cyclosporine 100 mg/mL Oral Liquid (Solution, 30 mL)	FIN	F 004 615
-------------------	--	-----	-----------

REFERENCES

1.	Solutions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 195.
2.	Olive Oil. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 470.
3.	Alcohol. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 17.
4.	Ciclosporin. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1822.
5.	Cyclosporins (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #2752
6.	Cyclosporine (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 2044.
7.	Oleoyl Polyoxylglycerides (Monograph). <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 1290.
8.	USP <795>. <i>United States Pharmacopeia XXXII / National Formulary 27</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 314.

DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.